BillionToOne (BLLN) stock
BLLN's Quality Score rose 3 points on Mon, Oct 26, to 15. Its daily swings narrowed into the quietest 25% of the last 100 days (2 chart checks started). 1 more reason, for Pro members.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on BLLN
| The company | Sales up 106% a year vs 25% for its peers |
| Latest filing | 10-Q, Aug 5 |
4 more reasons behind BLLN's 15, for Pro members.
BLLN in the news
TodayNo story names it yet.
What's next
Fri Nov 6: One year since its IPOListed Nov 6, 2025 at $60.
BLLN catalysts
After its last 4 reports it closed -10.2% on average, higher 1 of 4 times.
Why BLLN scores 15
ExcellentChoppy, 6 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. BLLN scores 15 today, against a median of 9.5 over its last 20 recorded sessions.
- +6Chart checks 6 of 14 firing right now, one point each
- +3Growth sales up 90% on the year, gross margin up 10.3 points
- Long-term trend adds
- Run-up adds
- Profit adds
- Persistence adds
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
BLLN has 6 of 14 chart checks firing
BLLN RSI today: 58.8, above its 50-day and 200-day averages
- RSI 1458.8
- MACD (12, 26, 9)Above signal
- 50-day average$102.06
- 200-day average$96.04
- 50/200 crossNo cross
- ADX 1415.0
- Support$90.48
- Resistance$127.72
- High since listing$150.44
- Low since listing$61.96
- Chart patternTriangle
- Bollinger Bands (20, 2)Inside
- Volume0.8x
The deep dive on BLLN
- What it does and how it makes moneySEC filing · Mar 11, 2026SEC filing · Mar 11, 2026
- Where it stands
- Who holds and trades it
- Against its closest peers
How BLLN ranks in Diagnostics
BLLN is #7 of 17 by Quality Score among Services-Medical Laboratories.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| 7 |
Sales over four quarters against a year before: BLLN +90%, VCYT +17%, GH +43%.
When does BLLN report earnings, and what happens after?
Reports Wed Nov 4, after the close (in 9 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What BLLN reported on Aug 5, 2026
The quarter
The figures are not read from the release yet.
“The increase in total revenue was driven by a 35% increase in the number of total tests delivered and a 21% increase in Overall ASP.”
Where the sales came from
BLLN's results filing gives no sales by line in a table we read.
The outlook
No outlook figures read from this release.
In the company's words
“BillionToOne also expects to operate the business such that it will continue to generate profitability similar to current levels, even with significant continued investments.”
From its results filing (SEC filing · Aug 5)
The numbers
- $5B
- today
- $397M
- up 90.1% on the year
- $33.2M
- last 12 months
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 5, 2026 | -29.9% | -38.9% | -35.0% |
| May 6, 2026 | +0.3% | +14.1% | +11.3% |
| Mar 4, 2026 | 0.0% | -10.7% | -16.7% |
BLLN's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold BLLN?
In ETFs: BLLN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About BillionToOne
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Listed on Nasdaq on Nov 6, 2025, and is 86% above its $60 offer price now. Its IPO filing and first days
What BillionToOne says it competes with
“As a result, each of our products faces competition from a number of established and emerging companies.”
BLLN's score card
Pro members see every line of every stock's score.
- What would move BLLN's score: 4 things
- 1 more filing explained, a plain line each
- Real-time prices, no delay
Straight Answers
Is BLLN a good stock to buy? What its Quality Score says
BLLN scores 15 today, which Breakaway calls Excellent. It is #7 of 17 in Services-Medical Laboratories by Quality Score, with 6 of 14 chart checks firing. Shares: 4.5 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is BLLN's Quality Score?
BLLN scores 15 today, which Breakaway calls Excellent (15 to 19). That is #7 of 17 in Services-Medical Laboratories by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BLLN's 15.
When does BLLN report earnings?
Reports Wed Nov 4, after the close, a date the company confirmed. BLLN closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.